H.C. Wainwright analyst Ed Arce lowered the firm’s price target on Arbutus Biopharma to $6 from $7.50 and keeps a Buy rating on the shares post the Q3 results.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on ABUS:
- Arbutus Reports Third Quarter 2022 Financial Results and Provides Corporate Update
- Arbutus Biopharma expects cash to fund operations into 2Q24
- Arbutus Biopharma reports Q3 EPS (12c), consensus (13c)
- Arbutus to Present at Jefferies London Healthcare Conference
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue